Actavis to trial Mirvaso competitor


An interesting development in rosacea clinical trials is the emergence of a new company called Actavis.

Actavis have listed a large trial where they plan to test their Brimonidine Gel against Galderma’s recently FDA approved Brimonidine-based Mirvaso Gel.

The large Phase 3 trial will compare the response after 7 days.

Up to 462 patients in 16 locations across the US will be examined.

The study was due to start in July and complete this month.

This trial announcement does not address how Actavis, a maker of generic prescriptions, will be able to market a treatment that is covered by patents owned by Galderma.

Clinical Trial NCT02289352

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

Sponsor: Actavis Inc.
Collaborator: Watson Laboratories, Inc.

Full Title: A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso (Brimonidine) Topical Gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

Primary Outcome Meansure: Proportion of patients with a clinical response of treatment success on Day 7 (± 1). Treatment success is defined as at least a 2-grade improvement on both CEA and PSA scores from baseline (pre-dose) on Day 7 (± 1) to 6 hours post-application on Day 7 (± 1).

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

8 Reader Comments

  1. John Betts says:

    Not directly connected but this is interesting “Actavis to buy Allergan”


  2. Yes Actavis suddenly became a lot more interesting to rosacea sufferers.

  3. This can only be good news,as treatment for rosacea runs over months any treatment that can under cut that time can only be great news for all people who suffer ROSACEA….

  4. Rob says:

    All of this kind of news is encouraging but disheartening at the same time, for example there was an article about 1% ivermectin cream with great potential that was written early this year stating patent approval later this year, well it’s pretty much already later this year and no word whatsoever and that seems to be the norm. A word to big drug representatives.., If you are going to get us all excited about promising new product then periodic updates would be greatly appreciated otherwise please don’t say anything.

  5. B says:

    So is this a clinical trial of a generic version of Mirvaso?

  6. samoht says:

    any news about this ? what is going to happen with actavis ? are they having a product which will come to the market soon ?

  7. Marian says:

    had a bad reaction to mirvaso — how long before the redness from the reaction goes away

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.